Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

UnavailableCutTheCoronaClutter: Trump backs & world tests drug cocktail for Covid-19 based on new studies & why this virus so smart-- EP 423
Currently unavailable

CutTheCoronaClutter: Trump backs & world tests drug cocktail for Covid-19 based on new studies & why this virus so smart-- EP 423

FromThePrint


Currently unavailable

CutTheCoronaClutter: Trump backs & world tests drug cocktail for Covid-19 based on new studies & why this virus so smart-- EP 423

FromThePrint

ratings:
Length:
16 minutes
Released:
Mar 22, 2020
Format:
Podcast episode

Description

#Coronavirus #CutTheCoronaClutterIn episode 423 of #CutTheClutter, specifically on Corona, Shekhar Gupta explains three key points from the global scientific debate on coronavirus--Chloroquine as an effective drug, two studies on the usage of this drug - one French study & one Chinese. And Crocin or Brufen, how to choose!Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial-https://www.medrxiv.org/content/10.1101/2020.03.16.20037135v1Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro-https://www.nature.com/articles/s41421-020-0156-0Why the Coronavirus Has Been So Successful:https://www.theatlantic.com/science/archive/2020/03/biography-new-coronavirus/608338/ 
Released:
Mar 22, 2020
Format:
Podcast episode

Titles in the series (100)

ThePrint.in is a news, analysis, opinion & knowledge venture, launched in August 2017 by editor Shekhar Gupta. It is sharply focused on politics and policy, government and governance. Its leadership team includes India’s most experienced & respected journalists with proven track records in the finest news organisations. We are headquartered in New Delhi, & are in the process of building a network across India because we believe in investing in high-quality investigative & questioning journalism.